ResearcherUniversité Paris CitéNo recent work listed
Sonia Zaibet
Matched on OpenAlex author ID A5051566357. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2022: 2 papers
Papers 2
- Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Co-author DOI 10.1038/s41416-022-01713-w↗
- Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world A… Co-author DOI 10.1038/s41416-022-01734-5↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Édouard Auclin · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Astrid Lièvre · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Matthieu Sarabi · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Dominique Béchade · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Julien Edeline · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Julien Taı̈eb · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Simon Pernot · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- Marine Gilabert · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
- David Tougeron · 2 shared papers, 2022 · strength 0.26
- Paper Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adeno… DOI 10.1038/s41416-022-01713-w↗
- Paper Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic p… DOI 10.1038/s41416-022-01734-5↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.